##### Volume 28, Number 1—January 2022

*Synopsis*

###
Extensively Drug-Resistant Carbapenemase-Producing *Pseudomonas aeruginosa* and Medical Tourism from the United States to Mexico, 2018–2019

#### Table 3

ID no. | MIC, μg/mL |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|

AMK | ATM | FEP | CAZ | CZA | C/T | CIP | CST | DOR | GEN | IPM | LVX | MEM | TZP | TOB | |

15 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |

14 | 16 (S) | 32 (R) | 32 (R) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | 4 (I) | 16 (R) | >64 (R) | >8 (R) | 8 (R) | 64/4 (I) | >16 (R) |

22 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 64/4 (I) | >16 (R) |

1 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 64/4 (I) | >16 (R) |

3 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 64/4 (I) | >16 (R) |

5 | 64 (R) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 1 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |

9 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |

8 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |

10 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 2 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |

13 | 32 (I) | 16 (I) | 16 (I) | 32 (R) | >16/4 (R) | >16/4 (R) | >8 (R) | 2 (S) | >8 (R) | 4 (S) | >64 (R) | >8 (R) | >8 (R) | 32/4 (I) | >16 (R) |

*Isolates were tested against 15 antimicrobial drugs by using reference broth microdilution. All isolates were ST111, except for 14 which was a unique ST. AMK, amikacin; ATM, aztreonam; C/T, ceftolozane/tazobactam; CAZ, ceftazidime; CIP, ciprofloxacin; CST, colistin; CZA, ceftazidime/avibactam; DOR, doripenem; FEP, cefepime; GEN, gentamicin; I, intermediate; ID, identification; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; R, resistant; S, sensitive; ST, sequence; TOB, tobramycin; TZP, piperacillin/tazobactam.

^{1}These authors contributed equally to this article.

^{2}Members of this team are listed at the end of this article.

*The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.*